and cardio-facio-cutaneous syndrome 8 , providing further links between RAS mutation and disease.
To cell biologists, RAS serves as the paradigm of a monomeric GTPase switch, a protein that exists in two states depending on the guanine nucleotide that it binds. As a binary switch, RAS regulates the flow of information down several signalling pathways (FIG. 1) . Cell biologists have also devoted attention to RAS because it represents the archetypal CAAX protein. This class of protein terminates in a CAAX sequence, in which C is Cys, A is usually, but not always, an aliphatic amino acid and X is any amino acid. The CAAX sequence directs the post-translational modification (PTM) of the carboxyl terminus of the protein with a polyisoprenoid lipid which, in the case of RAS, is a farnesyl moiety. This modification converts an otherwise globular, hydrophilic protein to one that associates with the cytoplasmic leaflet of cellular membranes, a process that is required for RAS activation and signalling.
The first two decades of research into the cell biology of RAS were marked by an exponential growth in the understanding of how the exchange of GTP for GDP on this protein is regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) (FIG. 1a) . We now know that GEFs activate RAS by inducing the release of GDP and permitting GTP binding, whereas GAPs inactivate small GTPases like RAS by increasing their intrinsic rate of GTP hydrolysis to return the protein to the GDP-bound state. The effectors and downstream pathways regulated by RAS, as well as the enzymes that modify the C-terminal hypervariable region (HVR), which targets RAS to membranes, were also characterized 9 . More recent insights into RAS biology have been gained from experiments carried out in vivo and in cultured cells. For example, the generation of transgenic mice has confirmed what cell biologists and cancer geneticists already suspected: that there are significant biological differences between RAS isoforms 10 . Furthermore, although RAS was initially thought to be expressed on, and to signal exclusively from, the plasma membrane, live-cell imaging of fluorescently labelled RAS proteins has revealed that RAS traffics between various subcellular compartments, including the Golgi apparatus and endosomes, and that it is capable of signalling from multiple locations [11] [12] [13] [14] . It has become clear that PTMs control the localization of RAS proteins
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Cardio-facio-cutaneous syndrome
A rare genetic disorder that is characterized by a distinctive facial appearance, congenital cardiac malformations and learning difficulties. Like Noonan syndrome, it is a RASopathy caused by gain-of-function mutations, but in this case in the genes encoding KRAS, BRAF or MAPK/ERK kinase (MEK).
Nitrosylation
The modification of a Cys side chain sulphhydryl group with a nitrosyl group derived from nitric oxide.
G domain
The first 169 amino acids of RAS proteins, which fold into a globular, hydrophilic protein that contains a guaninenucleotide (G)-binding site.
Heterotrimeric G proteins
Members of the large subfamily of guanine-nucleotidebinding proteins that signal downstream of receptors that span the plasma membrane seven times. Composed of three subunits designated α, β and γ, of which the α-subunit binds nucleotide.
such as phosphorylation, nitrosylation, ubiquityl ation and peptidyl-prolyl isomerization.
The interaction of RAS with its myriad of GEFs, GAPs and effectors (FIG. 1c) has been the subject of numerous reviews (for example, see REF. 15 ) and are not discussed in detail here. Rather, this Review focuses on the PTMs that are largely responsible for the trafficking and localization of RAS proteins. These PTMs present targets for the development of small molecule inhibitors that might limit RAS activity and thereby have use as drugs for a wide range of disorders characterized by dysregulated signalling, including cancer.
RAS as a molecular switch
There are three RAS genes in mammalian genomes: HRAS, NRAS, and KRAS 16 . Because the transcript from the KRAS locus can be alternatively spliced, the three genes give rise to four protein isoforms: HRAS, NRAS, KRAS4A and KRAS4B. These proteins are >90% identi cal in the first 168-169 amino acids (known as the G domain) but differ in the C-terminal 20 amino acids, which are known as the HVR (FIG. 2a) .
Each RAS protein is a 21 kDa guanine nucleotide binding protein with intrinsic GTPase activity and is therefore designated a small, or monomeric, GTPase, distinguishing RAS proteins from the α-subunits of hetero trimeric G proteins. The conformation of one surface of RAS proteins, consisting of the switch I and switch II regions, changes radically when GTP is substituted for GDP in the guanine-nucleotide-binding pocket 17 . This is the physical basis for the molecular switch that is at the core of RAS as a regulatory machine. RAS proteins transduce signals by interacting with effectors only when in the GTP-bound conformation. Thus, on-off signalling through RAS is ultimately determined by the factors that initiate GTP-GDP exchange and those that affect its GTPase activity.
RAS proteins are activated by GEFs, eight of which are encoded in mammalian genomes 15 . These include two isoforms each of Son of sevenless (SOS) and RASspecific guanyl-nucleotide-releasing factor (RASGRF), and four isoforms of RAS-specific guanine-nucleotidereleasing protein (RASGRP) (FIG. 1c) . Each GEF contains a CDC25 homology region, which is the catalytic domain Figure 1 | RAS signalling. a | The GDP-GTP cycle of RAS is shown. Inactive, GDP-bound RAS is activated by a guanine nucleotide exchange factor (GEF), which induces the release of GDP and thereby permits GTP to bind. GTP loading induces a marked conformational change in RAS that allows it to bind effectors via their RAS-binding domains (RBDs). The 'on' state of RAS is limited by its slow intrinsic GTPase activity, which is accelerated up to 10 5 -fold by the binding of a GTPase-activating protein (GAP), allowing RAS to return to its inactive, GDP-bound state. b | The RAS-RAF1-extracellular signal-regulated kinase (ERK) pathway. This pathway is engaged by protein Tyr kinase receptors (PTKRs), which are activated by growth factor binding. The adaptor protein growth factor receptor-bound 2 (GRB2) binds to activated (that is, phosphorylated) RTKs. GRB2 also binds the GEF Son of sevenless (SOS) and brings it to the membrane, where it can activate RAS. RAS initiates downstream signalling by bringing RAF1 to the membrane and activating its kinase activity. This is the best-characterized RAS-regulated pathway and it is frequently dysregulated in cancer. c | Multiplex regulation of, and signalling from, RAS. The various families of GEFs, GAPs and effectors that have been reported to regulate RAS or transmit signals from RAS·GTP are shown. CAPRI, calcium-promoted RAS inactivator; GAP1
IP4BP
, GAP1 InsP 4 -binding protein; MEK, MAPK/ERK kinase; NF1, neurofibromin 1; PLCε, phospholipase Cε; PI3K, phosphoinositide 3-kinase; RALGDS, RAL guanine nucleotide dissociation stimulator; RASAL, RASGAP-activating-like; RASGRF, RAS-specific guanyl-nucleotide-releasing factor; RASGRP, RAS-specific guanine-nucleotide-releasing protein; RASSF, RAS association domain-containing family; RIN1, RAS and RAB interactor 1; SYNGAP, synaptic RASGAP; TIAM1, T lymphoma invasion and metastasis-inducing 1.
SH2 domain
(SRC homology 2 domain). One of several types of domain found in numerous signalling molecules that bind to phosphotyrosine in the context of adjacent amino acids.
that stimulates the release of GDP. GDP release promotes GTP-binding because GTP is ten times more abundant than GDP in the cytosol. SOS is the best-characterized RAS-specific GEF (RASGEF), owing to the fact that its role in the RAS-mitogen-activated protein kinase (MAPK) pathway is firmly established. SOS binds constitutively to the adaptor protein growth factor receptorbound 2 (GRB2), and this complex is brought, via the SH2 domain of the adaptor, to protein Tyr kinase receptors (PTKRs) at the plasma membrane, which have been activated by the phosphorylation of specific Tyr residues in their cytosolic domains (FIG. 1b) . The translocation of the GRB2-SOS complex from the cytosol to the membraneassociated PTKR is aided by the plextrin homology (PH) and histone homology domains of SOS, both of which bind to negatively charged phospholipids 18, 19 . The intrinsic GTPase activity of RAS is very weak (k cat ≈ 2 × 10 -4 s -1 ) 20 . The rate of catalysis can be increased by a factor of up to 10 5 by the action of GAPs, and it is this class of protein that negatively regulates RAS and limits signalling. Mammalian genomes encode seven RAS-specific GAPs (RASGAPs), the best studied of which are p120 RASGAP (also known as RASA1) and neuro fibromin 15 . The others are synaptic RASGAP (SYNGAP), GAP1 m (also known as RASA2), GAP1 InsP 4 -binding protein (GAP1 IP4BP ; also known as RASA3) and two calcium-regulated GAPs, calcium-promote d RAS inactivator (CAPRI; also known as RASA4) and RASGAP-activating-like (RASAL) 21 . RASGAPs function by stabilizing the transition state of the nucleophilic attack of water on GTP. They accomplish this by inserting an ' Arg finger' into the active site of the GTPase 22 . Oncogenic mutations of RAS, such as the prevalent Gly12Val mutation, prevent GAP proteins from increasing the catalytic rate of the GTPase and thereby lock RAS in the GTP-bound state 23 .
Molecular and cellular effects of RAS RAS regulates many cellular functions, including gene expression, proliferation, survival, differentiation, cell cycle entry and cytoskeletal dynamics. Dysregulation of these cellular functions is a hallmark of cancer 24 . The biological effects of RAS proteins are specified by the pathways that they regulate, which, in turn, are determined by the effectors with which they interac t. Genetic studies in Drosophila melanogaster and Caenorhabditis elegans, which were validated by concurrent biochemical studies, established RAF1 as the first known RAS effector [25] [26] [27] [28] [29] [30] . RAF1 is the first kinase in the MAPK cascade, which proceeds through the activation of MAPK/ERK kinase (MEK; also known as MAPKK) and extracellular signalregulated kinase (ERK) (FIG. 1b) . Numerous studies have implicated this pathway in biological processes as diverse as the negative selection of T lymphocytes in the thymus 31 and the proliferation of epithelial cells 10 . The central role of the RAS-MAPK pathway in many cancers is substantiated by the fact that multiple nodes in this cascade have been identified as naturally occurring oncogenes, including mutant forms of the genes encoding epidermal growth factor receptor (EGFR), RAS, RAF and ETS.
Besides RAF1, at least six other families of proteins have been shown to interact with RAS in a GTPdependent fashion and are therefore also considered to be effector proteins 9 (FIG. 1c) . Of these, phosphoinositide 3-kinase (PI3K) and a family of RAL-specific GEFs, which includes RAL guanine nucleotide disso ciation stimulator (RALGDS), have been the most extensively studied. The ability of these effectors to contribute to oncogenesis is established, in part, by the fact that mutant forms of these proteins are themselves onco proteins 32, 33 . In addition, their ability to promote oncogenesis has been established in animal models. For example, mice deficient in RALGDS are protected from RAS-driven skin cancer 34 . Knock-in mice homozygous for a PI3K p110α allele lacking a RAS-binding domain were protected from lung tumours induced by oncogenic KRAS4B 35 . Another important RAS effector is T lymphoma invasion and metastasis-inducing 1 (TIAM1), a RAC-specific GEF that links RAS signalling to RAC 36 , which is a RHO family GTPase that regulates the actin cytoskeleton and activates p21-activated kinases (PAKs) and JUN N-terminal kinase (JNK). Finally, phospholipase Cε (PLCε) is a RAS effector that enables RAS to directly stimulate the production of the second messengers diacylglycerol and calcium 37 . Although TIAM1 and PLCε are not proto-oncoproteins, silencing the gene that encodes either of these effectors ameliorates HRAS-driven oncogenesis in a murine skin tumour model 38, 39 .
Box 1 | PTMs of RAS
Post-translational modification (PTM) of proteins is exceedingly common, according to Princeton's Proteome-Wide PTM Statistics Curator. The purpose of PTM is to extend the complexity and function of proteins, which are constructed from only 20 amino acids. PTMs have numerous roles, ranging from allowing proper folding and localization, to signalling for protein senescence and degradation. Readily reversible PTMs, such as phosphorylation, are used extensively in signalling pathways as the 'molecular currency' that transmits information. It is therefore not surprising that a signalling molecule as important as RAS can be modified post-translationally in multiple ways, including by farnesylation, palmitoylation, methylation, peptidyl-prolyl isomerization, phosphorylation, nitrosylation, monoubiquitylation and diubiquitylation, as well as by proteolytic removal of a carboxy-terminal pro-peptide (FIG. 6) .
The mechanism and function of each RAS PTM has been fairly well characterized. Farnesylpyrophosphate is a lipid intermediate in the cholesterol biosynthetic pathway, and it is added to the CAAX Cys of RAS 44 by farnesyltransferase 45 via a stable thioether linkage. Palmitate, which is an abundant saturated (acyl) fatty acid that is used to modify many proteins, is added to one or two Cys residues immediately upstream of the RAS CAAX sequence 59 by one or more palmitoyl acyltransferases (PATs) 62 via a labile thioester bond. The reversal of this modification is catalysed by one or more thioesterases, such as acyl-protein thioesterase 1 (APT1) 77 . The AAX amino acids of the CAAX sequence are substrates for an endoprotease designated RAS-converting enzyme 1 (RCE1) 51 . Following RCE1-mediated proteolysis, the α-carboxyl group of the now C-terminal prenylcysteine of RAS is methylesterified by isoprenylcysteine carboxyl methyltransferase (ICMT) 52 . The Gly-Pro peptidyl-prolyl bond of HRAS at position 178-179 undergoes cis-trans isomerization catalysed by 12 kDa FK506-binding protein (FKBP12) 79 . Protein kinase C (PKC) phosphorylates KRAS4B on Ser181 (REF. 82 ). Cys118, which is conserved in all RAS isoforms, functions as a redox indicator that can be nitrosylated 91 . Finally, HRAS and KRAS can be monoubiquitylated and diubiquitylated on several Lys residues 87, 88 by the E3 ligase rabaptin 5-associated exchange factor for RAB5 (RABEX5) 89 . In addition to these endogenous PTMs, two pathogenic bacteria, Pseudomonas aeruginosa and Clostridium sordelli, produce toxins that can ADP-ribosylate 96 or glucosylate 97 RAS. From this brief overview, it should be apparent that RAS is a prolific signalling molecule that is involved both in normal cellular homeostasis and in pathologic conditions. Accordingly, the PTMs that regulate RAS proteins have great significance both in normal physiology and in disease.
Regulation of RAS by constitutive PTMs
In addition to GTP binding, RAS proteins must associate with cellular membranes in order to transduce signals. Membrane association constrains RAS in two dimensions and thereby greatly facilitates its interaction with GEFs and GAPs. Indeed, RASGEFs are primarily regulated through their translocation to membranes via domains that bind membrane proteins (for example, SH2) or membrane phospholipids (for example, PH). Activated RAS, in turn, recruits its effectors to membranes. In the case of RAF1, the membrane itself participates in its activation via a poorly understood mechanism 40 . Thus, RAS is not only an allosteric regulator of the RAF1 kinase but also a membrane tether for the protein 41, 42 . Nascent RAS is a globular, hydrophilic protein, and its association with cellular membranes is mediated by a series of PTMs, some of which are constitutive and occur immediately after translation, and some of which are conditional. Constitutive PTMs are discussed here, and conditional PTMs are discussed in the next section.
CAAX processing: prenylation, proteolysis and methyl ation. RAS is a member of a large class of proteins known as the CAAX proteins. The CAAX sequence is modified by three enzymes that work sequentially 43 . First, unmodified CAAX sequences serve as substrates for prenylation by one of two cytosolic prenyltransferases 44, 45 . If the amino acid in the X position is Leu 46 , as is the case for most RHO family GTPases and the γ-subunits of heterotrimeric G proteins, then geranylgeranyltransferase type I (GGTase I) adds a 20-carbon polyisoprene lipid to the CAAX Cys via a stable thioether bond. Geranylgeranylation of RHO proteins not only allows them to associate with membranes, upon which they exert their biological effects, but also promotes their association with a cytosolic chaperone, RHO-specific GDP dissociation inhibitor (RHOGDI). Because RHOGDI possesses a hydrophobic pocket into which the geranylgeranyl lipid is sequestered, it can regulate the trafficking of RHO proteins on and off membranes 47 . If the amino acid in the X position of CAAX is not Leu 46 , as is the case for all RAS proteins, then farnesyltransferase (FTase) modifies the CAAX Cys with a 15-carbon farnesyl lipid (FIG. 2b) . Farnesylation affords RAS proteins relatively weak affinity for cellular membranes 48 . Several farnesyl binding proteins that are analogous to RHOGDI, such as phosphodiesterase δ (PDEδ) 49 , have been described that may facilitate the trafficking of farnesylated proteins 50 . Proteins such as RAS that are modified only with a farnesyl lipid accumulate on the cytoplasmic face of the endoplasmic reticulum (ER) 11 , where they encounter the next CAAX-processing enzyme, RAS-converting enzyme 1 (RCE1). RAS prenylation is a prerequisite for the action of RCE1, not only because it is required for the colocalization of RAS and RCE1 on the ER, but also because of the substrate specificity of this protease. RCE1 is an endoprotease that removes the AAX amino acids so that the farnesylcysteine is the new C terminus 51 . RAS is then modified by another ER-resident These sequences contain all of the information required to target the different RAS proteins to various subcellular membrane compartments, as demonstrated by the fact that they can be used in isolation to target unrelated proteins in the same way. The CAAX motif is often considered the 'first signal' because a 'second signal' immediately upstream of that sequence is also required for plasma membrane targeting. For HRAS, NRAS and KRAS4A, the second signal consists of Cys residues that are palmitoylated. For KRAS4B, the second signal consists of a polybasic region with a net positive charge of eight. The Cys residues of the CAAX motifs that are farnesylated are shown in yellow. The Cys residues in the second signal region that are modified by palmitate are shown in green. The Lys residues of the polybasic region of KRAS4B are shown in pink, and Ser181, which is the principal site of phosphorylation, is show in blue. b | CAAX processing is catalysed by three enzymes that work sequentially: farnesyltransferase (FTase), RAS-converting enzyme 1 (RCE1) and isoprenylcysteine carboxylmethyltransferase (ICMT). FTase is a cytosolic enzyme that catalyses the first, and rate-limiting, reaction in the sequence. RCE1 is an endoplasmic reticulum (ER)-localized endoprotease that removes the AAX amino acids, rendering the farnesylcysteine the new carboxyl terminus. ICMT, which is also localized in ER membranes, methylesterifies the α-carboxyl group of the farnesylcysteine. S-adenosylmethionine (AdoMet) is used as the methyl donor in this reaction, generating S-adenosylhomocysteine (AdoHcy) as a product. The end result of these modifications is to convert the C terminus of RAS proteins from a hydrophilic domain to a lipidated, hydrophobic domain in which the charge of the C-terminal carboxylate is negated by methylation. The reactions catalysed by FTase and RCE1 are irreversible, whereas prenylcysteine carboxyl methylation catalysed by ICMT is readily reversible at physiological pH, although a specific esterase that catalyses the reverse reaction has not been identified.
enzyme, isoprenylcysteine carboxylmethyltransferase (ICMT), which catalyses the methyl esterification of the α-carboxyl group of the farnesylcysteine 52 . Of these three modifications, only the one catalysed by ICMT is reversible (FIG. 2b) . The end result of these three modifications is the remodelling of the C terminus of RAS proteins from a hydrophilic region to a hydrophobic one, which is capable of insertion into cellular membranes and is a requirement for the biological activity of RAS proteins.
There is no evidence that CAAX processing is regulated with respect to cell activation, metabolic status or cell cycle, suggesting that it is a 'housekeeping' process. One caveat is the recent description of the binding of a splice variant of SMGGDS, a GEF that is active against a wide range of small GTPases, to unprenylated RAS, which thereby retards its prenylation, suggesting a mode of regulation 53 . Two classes of drugs can block the prenylation of RAS and other proteins: statins, which inhibit 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) and therefore limit the availability of farnesyl pyrophosphate (an intermediate in the cholesterol biosynthetic pathway initiated by HMG-CoA reductase), and FTase inhibitors (FTIs), which directly inhibit farnesylation. A pool of unprocessed, endogenous RAS in the absence of prenylation-inhibiting drugs has not been described. RAS processed by the three sequential PTMs of the CAAX sequence can be distinguished from unprocessed RAS by SDS-PAGE because the processed form has a slightly faster electrophoretic mobility. The unprocessed form of endogenous RAS can be observed in SDS-PAGE only after treatment with statins or FTIs 54, 55 . Concordant with these results, whereas endogenous RAS is readily detected in the cytosolic fraction of cells treated with statin or FTI, the vast majority of RAS is in the membrane fraction of untreated cells (M. Zhou and M.R.P, unpublished observations). These findings argue strongly against the existence a pool of unprocessed RAS that is awaiting processing and suggest that CAAX processing follows translation immediately in an efficient and constitutive manner. Nevertheless, the CAAX processing pathway can be saturated: when RAS is overexpressed, a significant pool is unprocessed, based on the results of electrophoretic mobility and subcellular fractionation (M. Zhou and M.R.P, unpublished observations).
Although CAAX processing is necessary for the delivery of RAS proteins to, and their stable association with, the plasma membrane, it is not sufficient for these events. Elements within the HVR that are upstream of the CAAX sequence 56 are also required. These elements have been called 'second signals' for plasma membrane targeting. There are two types of second signal: one consists of Cys residues that serve as acceptor sites for palmitoylation (as found in HRAS, NRAS and KRAS4A) and the other consists of polybasic regions rich in Lys residues (as found in KRAS4B) (FIG. 2a) .
Palmitoylation as a second signal. The covalent attachment of the acyl chain of a fatty acid to a protein is known as protein acylation 57 . Although acyl chains of a variety of lengths have been shown to be incor porated into proteins, the 14-carbon myristoyl chain and the 16-carbon palmitoyl chain are the most commonly used. Myristoylation is largely restricted to the amino termini of proteins, whereas palmitoylation of Cys residues occurs throughout the polypeptide chain. The palmitoylatio n of RAS was first described 25 years ago 58 , and it was later appreciated that this PTM is isoform specific 59 . HRAS has two Cys residues that can accept palmitate (Cys181 and Cys184), whereas NRAS has only one (Cys181). Although the best studied splice variant of KRAS, KRAS4B, does not undergo palmitoylation, the other splice form, KRAS4A, is palmitoylated at Cys180 (REF. 60 ). Palmitate is linked to RAS via a labile thioester bond, and the modification is readily reversible 61 . A palmitoyl acyltransferase (PAT) capable of modifying RAS was recently identified as the DHHC9-GPC16 (DHHC domain-containing 9-Golgi complex-associate d protein of 16 kDa) complex 62 , which is an orthologue of the yeast Erf4-Erf2 complex 63 . DHHC9-GPC16 is a member of a family of 25 PATs, which all contain a DHHC motif but differ in their subcellular localization and substrate specificity 64 . Whereas all members of this family have a DHHC motif, most do not have binding partners that are analogous to GPC16. Knockdown studie s suggest that DHHC9-GPC16 is not the only PAT with activity toward RAS 65 . DHHC9 and other DHHC motif-containing members of this family of enzymes are transmembrane proteins. Thus, CAAX processing of RAS, which affords the protein some affinity for membranes, would appear to be a prerequisite for palmitoylation. However, RAS mutants in Saccharomyces cerevisiae that lack the CAAX Cys can still be palmitoylated, demonstrating that prenylation is not absolutely required for palmitoylation, at least in yeast 66 . Palmitoylation is required for the trafficking of NRAS and HRAS from the endomembrane system to the plasma membrane 11, 67 (FIG. 3) . Palmitoylation of RAS takes place on the cytosolic face of the Golgi apparatus, where DHHC9-GPC16 resides. Farnesylated RAS has only modest affinity for membranes, but RAS that is both farnesylated and palmitoylated has more than 100-fold higher affinity 68, 69 and therefore palmitoylation of RAS at the Golgi serves as an affinity trap for the protein. The high-affinity binding to membranes of dually lipidated proteins promotes their subcellular trafficking through vesicular transport.
The polybasic region as a second signal for KRAS4B. KRAS4B is unique among RAS proteins, in that it cannot be palmitoylated. Nevertheless, as is the case for all CAAX proteins, it still requires a second signal for trafficking to the plasma membrane 56 . The KRAS4B second signal consists of a Lys-rich domain in the HVR that has a net positive charge of eight. Thus, although no PTM is required to create this second signal, the motif is considered here because it complements farnesylation and can itself be modified by a PTM (see below). The polybasic region forms an electrostatic interaction with the negatively charged headgroups of the inner leaflet of the plasma membrane. Neither this electrostatic interaction alone nor the insertion of the farnesyl group on RAS into the phospholipid bilayer provides sufficient affinity for Nature Reviews | Molecular Cell Biology stable membrane association, but the two interactions together provide enough affinity for relatively stable membrane association. Although the steady-state distribution of KRAS4B appears to be predominantly at the plasma membrane, molecular-trapping studies in live cells have revealed that the interaction of KRAS4B with the plasma membrane is dynamic 70 .
Palmitoylation-depalmitoylation cycling. Unlike farnesylation, palmitoylation is readily reversible under physiological conditions. Indeed, it was shown more than 25 years ago that the half-life of palmitate on RAS was considerably shorter than the half-life of the protein 61 . More recently, it was found that NRAS and HRAS undergo an acylation-deacylation cycle that is linked to RAS trafficking to and from the Golgi apparatus 71, 72 (FIG. 3) . Anterograde trafficking from the Golgi to the plasma membrane requires palmitoylation and proceeds via vesicular transport 11, 67 . The localization of DHHC9-GPC16 on the Golgi and the fact that dually lipidated proteins are affinity trapped by membranes supports this model. Photobleaching 71, 72 and photo activation 71 studies have revealed that retrograde trafficking of RAS from the plasma membrane to the Golgi requires depalmitoylation and is too rapid to occur via vesicular trafficking. These observations support the current model, in which NRAS and HRAS are palmitoylated on the Golgi apparatus and thereby affinity trapped in a membrane compartment, transported to the plasma membrane on vesicles and, after a certain period of time, depalmitoylated there and released back into the cytosol (FIG. 4) . From the cytosol, RAS proteins can diffuse back to the Golgi for another round of palm itoylation and a return to the plasma membrane. Evidence that RAS signalling from the Golgi apparatus differs from RAS signalling from the plasma membrane in terms of relative downstream pathway use 12,13, [73] [74] [75] and, in the case of T lymphocytes, in biological outcome 31 , supports the idea that the acylation-deacylation cycle is a way to modulate signalling.
There is no evidence that palmitoylation of RAS by DHHC9-GPC16 or any other PAT is regulated, suggesting that, like farnesylation, palmitoylation is an im mediately post-translational housekeeping modification, although this is an under-investigated area. By contrast, there is evidence that depalmitoylation is regulated by GTP-loading of HRAS 76 . Thus, elucidation of the mode of regulation of depalmitoylation rests, to some extent, on identifying the mechanism of palmitate removal. The thioester linkage between palmitate and its substrates is quite labile, and one school of thought holds that de palmitoylation may not be enzymatic. Another school holds that there are one or more RAS-specific palmitoyl thioesterases that catalyse the hydrolysis reaction. One candidate is acyl-protein thioesterase 1 (APT1) 77 . However, this protein has many other substrates and is found in the cytosol, raising the question of how it could have access to the palmitate modifications of membrane-bound RAS 78 . A recent, highly innovative study used semisynthetic RAS proteins with cleavable or non-cleavable acyl modifications and came to the conclusion that, although RAS can be palmitoylated only on the Golgi, depalmitoylation can occur anywhere in the cell 65 . This suggests a model whereby the entropy that would otherwise distribute RAS over all intracellular membranes is overcome by the restricted localization of palmitoylation on the Golgi and unidirectional vectorial vesicular transport 65 .
Regulation of RAS by conditional PTMs
As discussed above, farnesyl and palmitoyl lipidation of the C-terminal membrane-targeting domain of RAS are constitutive modifications that follow translation rapidly and efficiently. RAS proteins can also be modified in several other ways that are conditional upon cell activation, redox state or microbial pathogenesis. The conditions upon which these modifications occur, and their physiological relevance, are only beginning to be elucidated. These modifications are discussed below. and, after farnesylation, it gains affinity for, and is transported to, membranes of the endoplasmic reticulum (ER) (b), where it encounters the subsequent CAAX-processing enzymes RAS-converting enzyme 1 (RCE1) (c) and isoprenylcysteine carboxylmethyltransferase (ICMT) (d). Following CAAX processing, KRAS4B deviates from the path of the palmitoylated RAS isoforms and proceeds directly to the plasma membrane (e) via a poorly understood pathway that may involve cytosolic chaperones. NRAS and HRAS proceed to the cytosolic face of the Golgi apparatus, where they are palmitoylated by DHHC9-GCP16 (DHHC domain-containing 9-Golgi complex-associated protein of 16 kDa) and thereby are trapped in that membrane compartment (f). From the Golgi, they traffic via vesicles to the plasma membrane (g). Upon phosphorylation of Ser181, KRAS4B can be discharged from the plasma membrane and travel back to the endomembrane system (e). NRAS and HRAS are discharged from the membrane by depalmitoylation, and move by retrograde transport back to the Golgi for another round of palmitoylation (h). Cis-trans isomerization of the peptidyl-prolyl bond (molecular timer)
Cis-trans isomerization
Transformation, usually by an enzyme, of a peptide bond, or more commonly a peptidylprolyl bond, from a cis to a trans conformation or vice versa.
Myristoyl-electrostatic switch
A term used to describe the mechanism whereby the membrane association of N-myristoylated proteins, such as myristoylated Ala-rich C-kinase substrate (MARCKS), is modulated by phosphorylation of Ser residues in an adjacent polybasic region.
Peptidylprolyl isomerization. A recent study has implicated 12 kDa FK506-binding protein (FKBP12), a cis-trans prolyl isomerase, in the regulation of RAS depalmitoylation 79 (FIG. 4) . The extent of HRAS palmitoylation was shown to depend on the presence or absence of a Pro at position 179 in the HVR. FK506 and other chemical inhibitors of the prolyl isomeras e activity of FKBP12, including cycloheximide and rapamycin, inhibited HRAS depalmitoylation and this effect was recapitulated by silencing FKBP12. In addition, HRAS bound to FKBP12 in a palmitoylationdependen t fashion. Together, these observations suggest that isomerization of the Gly-Pro peptidyl-prolyl bond at position 178-179 of HRAS regulates depalmitoylation and thereby constitutes a molecular timer for acylation. Cis-trans isomerization about this bond, which accelerates RAS depalmitoylation, is catalysed by FKBP12. Thus, peptidyl-prolyl isomerization is the most recently recognized RAS PTM. Although originally thought to only play a part in the proper folding of nascent proteins, cis-trans isomerization of peptidylprolyl bonds is increasingly recognized as a mechanism for signalling, particularly when a molecular timer is required 80 .
Phosphorylation and the farnesyl-electrostatic switch. KRAS4B was first shown to be phosphorylated by protein kinase C (PKC) at its C terminus in 1987, although no biochemical effect of this modification was reported 81 . Recently, the PKC phosphorylation site was mapped to Ser181, which is positioned within the polybasic region 82 . Phosphorylation is stimulated by a calcium ionophore, implicating a conventional PKC as the relevant kinase, although which member (or members) of this class of kinase is involved in regulating KRAS4B has not been determined. The physiological stimulus that induces KRAS4B phosphorylation also remains to be elucidated. Phosphorylation of Ser181 reduces the net charge of the polybasic region, causing KRAS4B to lose affinity for the plasma membrane and to accumulate on endomembranes. This mechanism is reminiscent of the myristoyl-electrostatic switch, which regulates the membrane association of the myristoylated Ala-rich C-kinase substrate (MARCKS) 83 , and therefore it has been called the farnesyl-electrostatic switch (FIG. 5) .
KRAS4B is not the only small GTPase that has a farnesyl-electrostatic switch; the RHO family GTPase RND3 is also regulated in this fashion 84 . Furthermore, RALA, a RAS family GTPase, is phosphorylated on Ser194 in its HVR by Aurora A kinase, and this causes it to translocate to mitochondria where it regulates mitochondrial fission 85 . Interestingly, when KRAS4B has an activating mutation, relocation to endomembranes as a consequence of the farnesyl-electrostatic switch is associated with cell death 82 . The mechanism for the cell toxicity is unclear but, paradoxically, the anti-apoptoti c protein B-cell lymphoma-extra large (BCL-XL) is required 82 . In recent work, we found that the mechanism of diminished cell survival involves the capacity of phosphorylated KRAS4B to interfere with the ability of BCL-XL to sensitize inositol-1,4,5-trisphosphate receptors in a way that promotes the transfer of calcium from the ER to mitochondria, which is required for efficient respiration (P. Sung and M.R.P, unpublished observations). The farnesyl-electrostatic switch of oncogenic KRAS4B might be exploited in the development of anticancer drugs. Dissociation of KRAS4B from the plasma membrane was also observed in neurons stimulated with glutamate, and a mechanism involving calcium and calmodulin binding to the KRAS polybasic region was proposed 86 . Because calmodulin binds the polybasic region of KRAS4B and other proteins through a calcium-regulated electrostatic inter action, phosphoryl ation of Ser181 would be expected to diminish calmodulin binding. Thus, under conditions in which the farnesyl-electrostatic switch is engaged by the phosphorylation of KRAS4B on Ser181, calmodulin is unlikely to play a part in causing the dissociation of KRAS4B from the plasma membrane. During acylation, the acyl chain of a fatty acid is covalently attached to a Cys residue of a protein via a labile thioester linkage. The most common fatty acid used for this purpose is palmitate, which contributes its 16 carbon saturated acyl chain to the protein. The enzymes that catalyse this lipidation reaction are known as palmitoyl acyltransferases (PATs). HRAS is palmitoylated on the Golgi apparatus by the PAT DHHC9-GCP16 (DHHC domain-containing 9-Golgi complex-associated protein of 16 kDa) (step 1) and sent to the plasma membrane through vesicular transport (step 2). Once on the membrane, HRAS is susceptible to depalmitoylation by a thioesterase, such as acyl-protein thioesterase 1 (APT1). Palmitoylated HRAS binds to 12 kDa FK506-binding protein (FKBP12), which catalyses cis-trans isomerization of the peptidyl-prolyl bond immediately adjacent to the palmitoylated Cys (step 3). This isomerization constitutes a molecular timer that promotes depalmitoylation, which allows HRAS to leave the plasma membrane (step 4) and diffuse back to the Golgi (step 5) for another round of acylation. FK506, rapamycin, cycloheximide (CHX) and other drugs that inhibit the prolyl isomerase activity of FKBP12 augment HRAS palmitoylation by inhibiting depalmitoylation. Ubiquitylation. HRAS, NRAS and KRAS4B were recently shown to be substrates for monoubiquitylatio n and diubiquitylation 87, 88 . The conditions under which RAS becomes ubiquitylated have not been determined. Nor have all of the ubiquitin acceptor sites been mapped, although, based on mutagenesis studies, several surface-exposed Lys residues are candidates 87 . Mass spectrometry of affinity-purified, dual epitopetagged HRAS from cells expressing tagged ubiquitin revealed monoubiquitylation and diubiquitylation on Lys117, Lys147 and Lys170 (REF. 88 ). The E3 ligase that is responsible for these modifications was identified as rabaptin 5-associated exchange factor for RAB5 (RABEX5; also known as RABGEF1) 89 . Furthermore, the RAS effector RAS and RAB inter actor 1 (RIN1) is required for RABEX5-dependent RAS ubiquitylation 89 . RIN1, through its function as a GEF for RAB5, is thought to promote the RAB5·GTP-dependent recruitment of RABEX5 to endosomal sites, where HRAS ubiquitylation takes place. Whereas the presence of HRAS that could not be ubiquitylated was rare on endosomes, HRAS that was artificially and constitutively ubiquitylated was enriched on endosomes. Thus, ubiquitylation regulates the trafficking of HRAS to and from endosomes. Importantly, the ubiquitin-mediated endosomal restriction of HRAS was also associated with a reduction in MAPK signalling, demonstrating that ubiquitylation is yet another PTM that regulates RAS compartmentalization and the spatial control of its signalling output. KRAS4B was recently found to be monoubiquitylated on Lys104 and Lys147 (REF. 88 ). This modification led to enhanced GTP loading and, in the setting of an oncogenic Val12 mutation, increased the affinity of KRAS4B for the downstream effectors RAF1 and PI3K.
Snitrosylation. Cys118 is highly conserved among RAS isoforms and orthologues, and it is the most surfaceexposed Cys on these GTPases. This residue was shown to be a redox switch more than 15 years ago 90 , and subsequent studies revealed that Cys118 could be nitrosylated when exposed to nitric oxide (NO) 91 . The mechanism of nitrosylation was later shown to be a direct interaction of the thiol of Cys118 either with a nitrogen dioxide radical (NO 2
• ), formed when NO interacts with O 2 , or with a glutathionyl radical (GS • ) 92 . S-nitrosylation does not alter the structure of RAS but leads to enhanced guanine nucleotide exchange 93, 94 , which promotes more efficient RAS activation. This has led to the speculation that RAS signalling can be modulated by redox reactions, although the physiological relevance of RAS S-nitrosylation remains to be determined.
Bacterial toxins and exoenzymes. The RAS superfamily of small GTPases is a favourite target of bacterial virulence factors that evolved as enzymes which modify eukaryotic signalling molecules. Most such toxins and exoenzymes target the RHO family of small GTPases, which regulate the actin cytoskeleton 95 . However, there are also bacterial enzymes that are active against RAS. Exoenzyme S (ExoS) of Pseudomonas aeruginosa is an ADP-ribosyl transferase that modifies RAS. ExoS adds ADP-ribose to Arg41 and Arg128 of RAS, leading to inefficient guanine nucleotide exchange 96 . Lethal toxin of Clostridium sordelli is a monoglucosyltranferase that uses UDP-glucose as a substrate and glucosylates RAS on Thr35. Toxin B of Clostridium difficile has a similar activity towards RHO proteins 97 . Glucosylation of RAS inhibits signalling to MAPK 98 . Whereas nascent RAS requires stoichiometric CAAX processing for maturation as a membrane protein, it is now clear that the mature protein can be modified in ways that modulate subcellular trafficking and signalling (FIG. 6) . Although these modifications are conditional, in the sense that pools of RAS exist in both the modified and unmodified forms, the conditions in which these PTMs are stimulated, the stoichiometry of the modifications and their biological significance remain to be elucidated.
Consequences of RAS PTMs
The primary function of most of the PTMs of RAS is to deliver the molecule to the right place within the cell. In this section, we describe how the PTMs discussed above influence RAS trafficking to the plasma membrane and its partitioning into membrane microdomains. The myristoylated Ala-rich C-kinase substrate (MARCKS) protein depicted above KRAS4B is known to associate conditionally with the plasma membrane by virtue of a myristoylated amino terminus and a nearby polybasic region. Protein kinase C (PKC)-induced phosphorylation of Ser residues (shown in pink) within the polybasic region of MARCKS partially neutralizes its positive charge and allows MARCKS to fall off the membrane in a process known as a myristoyl-electrostatic switch. The carboxy-terminal farnesyl modification of KRAS4B and the nearby polybasic region are similarly regulated by a farnesyl-electrostatic switch, which is activated by PKC-mediated phosphorylation of Ser181. Ser171 is also a phosphate acceptor that may contribute to, but is not required for, the operation of the farnesylelectrostatic switch, which is primarily regulated by phosphorylation of Ser181. Specifically, phosphorylation of Ser181 in KRAS4B promotes the dissociation of RAS from membranes. The inset shows that green fluorescent protein (GFP)-bound KRAS4B dissociates from the membrane and is internalized in live Jurkat T cells upon exposure to the PKC agonist phorbol myristate acetate (PMA). Nature Reviews | Molecular Cell Biology 
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RAS trafficking. CAAX processing and palmitoylation of RAS were originally thought to be a way to convert a globular hydrophilic protein into one with a hydrophobic C terminus that has generalized affinity for cell membranes. The discovery that two of the CAAX processing enzymes, ICMT and RCE1, are polytopic membrane protein s restricted to the ER revealed that RAS trafficking is more complex than originally believed 52, 99, 100 . Our current understanding of RAS trafficking begins in the cytosol, where nascent RAS is synthesized on free polysomes (FIG. 3) . FTase, the first, and rate-limiting, of the CAAX processing enzymes, is cytosolic 101 . Once farnesylated, RAS gains modest affinity for membranes, particularly those of the ER. How farnesylated RAS is transferred from the cytosolic FTase to membranes is a matter of speculation. Are there chaperones involved? If so, does a single chaperone or family of chaperones both deliver farnesylated RAS to RCE1 and ICMT at the ER and also retrieve the fully CAAX-processed product? The existence, and physiological role, of RHOGDI, a geranylgerany l-binding chaperone for RHO family GTPases 47 , has led RAS biologists to speculate that an analogous chaperone may exist for farnesylated proteins. Several proteins have been identified in yeast twohybrid screens as farnesyl-binding proteins, including PDE6δ 102 , prenylated RAB acceptor 1 (PRA1) 103 and galectin 104 . Among these proteins, PDE6δ is particularly intriguing because its farnesyl-binding domain bears structural similar ity to RHOGDI and because it was recently reported that its capacity to bind RAS and other farnesylated proteins is regulated by its interaction with the non-prenylated small GTPases ADP-ribosylation factorlike 1 (ARL1) and ARL2 (REF. 49 ). Moreover, a recent study reported that PDE6δ is required for proper trafficking of RAS and other farnesylated proteins, as well as for efficient RAS signalling 50 . Another intriguing possibility is that FTase itself might serve as the chaperone, as it was found to have an unusual mode of catalysis: it has the abilit y to retain its product in a secondary exit surface near the active site 101 . Whether or not chaperones play a role in RAS trafficking, the first membrane compartment visited by nascent RAS is the ER. The basis for the particular affinity of RAS for ER membranes is not universally accepted or understood, but it may relate to the biophysical properties of this compartment and the branched, unsaturated nature of the polyisoprene lipid that is added by farnesylation. Some investigators have argued that green fluorescent protein (GFP)-tagged prenylated proteins appear on the ER simply because the ER constitutes by far the greatest reservoir of membrane in the cell 65 . However, without a second signal, GFP-tagged RAS and other CAAX proteins appear neither on the plasma membrane nor on other abundant membrane-bound organelles, such as mitochondria 11 , calling into question the notion of nonspecific membrane association. The particular affinity of RAS for the ER makes teleological sense, as it is here that the next two enzymes in the CAAX-processing cascade (RCE1 and ICMT) reside. Indeed, it is conceivable that RCE1 helps attract proteins with farnesylated CAAX sequences to the ER and thereby accounts for the observed membrane localization.
Once CAAX processing is complete, RAS isoforms diverge in their subsequent trafficking 43 . Palmitoylated isoforms visit the cytoplasmic face of the Golgi, where they are acylated and thereby affinity trapped in Golgi membranes, from which they can be incorporated into transport vesicles and enter the secretory pathway. KRAS4B cannot be trapped on the Golgi and proceeds to the plasma membrane either by passive diffusion or by an as yet uncharacterized delivery system that could involve cytosolic chaperones. Recent observations have revealed that the plasma membrane is not the end of the road for palmitoylated RAS or KRAS4B. Palmitoylated RAS undergoes retrograde trafficking, which is mediated by the acylation cycle described above 71, 72 , and KRAS4B undergoes retrograde trafficking from the plasma membrane to endomembranes upon phosphorylation and engagement of the farnesyl-electrostatic switch 82 . RAS is also trafficked to endosomes by two routes, one from the plasma membrane and one from the Golgi. RAS that is associated with clathrin-coated regions of the plasma membrane is internalized into primary endosomes during clathrin-mediated endocytosis. As clathrin-coated membrane domains also contain the activated PTKRs that signal through RAS and RAF1, all of these elements are present on these 'signalling endosomes' and signalling can persist 105 . Indeed, in some contexts, 
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endocytosis is absolutely required for RAS-MAPK signalling 106 . Recently, signalling endosomes were differentiated from their non-signalling counterparts by expression of APPL1 (adaptor protein containing PH domain, PTB domain and Leu zipper motif 1) 107 . APPL1 directly binds RAB5, PTKRs and the phospholipid bilayer, thus serving as a scaffold for signalling complexes that include RAS. The association of APPL1 with endosome membranes was dependent on low phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5) P 3 ) levels, suggesting that phosphoinositide remodelling interconverts signalling and non-signalling endosomes 107 . A second route to endosomes, which is taken by palmitoylated RAS, was recently described, in which NRAS and HRAS traffic from the Golgi to recyclin g endosomes and then on to the plasma membrane 108 . There remains some disagreement as to whether KRAS4B associates with, and signals from, endosomes like its palmitoylated cousins. Several groups reported that, whereas NRAS and HRAS were associated with endosomes, KRAS4B was not 87, 109, 110 . These data are consistent with the observation that diubiquitylation promotes the association of RAS with endosomes but, although all three RAS isoforms examined can be mono ubiquitylated, only NRAS and HRAS are diubiquityl ated 87 . More recently, KRAS4B was reported to associate with early endosomes in a clathrin-dependent fashion and then to traffic to late endosomes, leaving HRAS behind 111 . Moreover, KRAS4B was found to reside on, signal from, and undergo degradation in, late endosomes, lysosomes and multivesicular bodies 111 . Clearly, we have more to learn about RAS trafficking through the endosomal compartment.
Microdomain affinity and nanoclusters. RAS traffickin g does not end at the plasma membrane because this organelle is not homogeneous but rather is composed of several types of microdomains 112 . Like its trafficking between organelles, the partitioning of RAS into membrane microdomains is regulated by PTMs. The bestcharacterized microdomain is a cholesterol-dependent, liquid-ordered domain often referred to as a 'lipid raft' . Once thought to encompass relatively large patches of membrane analogous to the liquid-ordered domains observed in artificial bilayers 113 , cholesterol-dependent domains are now known to exist on a nanoscale, to be highly dynamic and to incorporate on the order of ten or fewer signalling molecules, such as RAS 114, 115 . In addition to lipid rafts, at least two cholesterol-independent microdomains have been detected, and these are also thought to be highly dynamic and to exist on a nanoscale level 112 . Microdomains serve to bring together multiple signalling components. In addition, nanoclusters have been shown to convert analogue RAS-MAPK signalling into a digital signal that improves fidelity 116 . Palmitoylation appears to be one of the strongest determinants of protein association with lipid rafts. Therefore, it is not surprising that HRAS, NRAS, and KRAS4B occupy distinct plasma membrane microdomains 115 . Inactive, GDP-bound HRAS has been found to group in nanoclusters of approximately six molecules within ordered, cholesterol-rich microdomains. Interestingly, exchange of GDP for GTP causes HRAS to lose affinity for the lipid raft domains and to migrate laterally into adjacent regions of disordered plasma membrane 117, 118 . Coincident with this migration is its interaction with a scaffolding protein, galectin 1, which acts to enrich GTP-bound HRAS in non-ordered microdomains 119, 120 . Surprisingly, although the final ten amino acids of HRAS, which encompass the CAAX sequence and both palmitoylation sites, are sufficient to direct plasma membrane localization, they cannot fully recapitulate the dynamic behaviour of fulllength HRAS with regard to plasma membrane nanoclusters and microdomains 115, 121 . Instead, additional elements within the HVR and even the G domain help stabilize the membrane orientation and microdomain preference of full length HRAS at the plasma membrane and thereby contribute to differential effector engagement [121] [122] [123] . Interestingly, the GTP binding status of NRAS also affects microdomain partitioning, but for this isoform it is the GTP-bound form that favours partitioning into cholesterol-dependent nanoclusters 124 , which in turn controls signal output. Thus, with regard to plasma membrane microdomains, monopalmitoylation versu s dipalmitoy lation appears to differentially control localization. Moreover, whereas HRAS that is monopalmitoylated on Cys181 behaves like NRAS, HRAS that is monopalmitoylated at Cys184 does not traffic efficiently to the plasma membrane 124 . Thus, it appears that the spacing between the prenyl and acyl modifications is also critical for proper trafficking and microdomain partitioning. The linker region comprising amino acids 170-179 within the HRAS HVR has also been shown to specifically contribute to the association of HRAS within non-raft microdomains 121 . KRAS4B partitions into cholesterol-independent microdomains that do not overlap with those into which GTP-bound HRAS partitions 115, 125 . Interaction with the galectin 3 scaffold enhances KRAS4B nanocluster formation 126 . Phosphorylation of GTP-bound KRAS4B on Ser181 reduces nanoclustering 127 . Thus, like palmitoylation, phosphorylation plays a part in nanocluster formation.
Generating a comprehensive model for how the C terminus of RAS proteins interacts with phospholipid bilayers is confounded by the inability to produce crystals of RAS that include its C terminus. All of the RAS structures that have been solved are from crystals of RAS proteins that lacked a C terminus, which is thought to be disordered 128 . However, recent molecular dynamic simulations and NMR data collected from full-length farnesylated HRAS in a 1,2-dimyristoylglycero-3-phosphocholine bilayer have provided computational models of membrane insertion and have revealed putative contributions of both the HVR and G domains in this process [129] [130] [131] . In these models, the GDP-bound conformation of HRAS favours electrostatic interactions between basic residues within its HVR and the inner leaflet of the plasma membrane. By contrast, residues within the α4 helix of the G domain facilitate the membrane association of GTPbound, active, HRAS, control its orientation with respect to the membrane and thereby contribute directly to effector binding specificity 132, 133 . Moreover, in these models, the depth of membrane insertion of palmitates was greater when HRAS was GTP-loaded, perhaps explaining the activation-specific association of HRAS with galectin 1 (REF. 130 ).
Exploiting RAS PTMs for therapy
Oncogenic mutations of RAS block the ability of GAPs to accelerate GTP hydrolysis. Thus, the most direct approach to therapies targeting RAS would be to develop drugs that relieve this block. Unfortunately, efforts along these lines in academic laboratories have all failed. In addition to GTP loading, CAAX processing is required for oncogenic RAS to transform cells 134 . Accordingly, many have looked to RAS post-translational processing as an alternative approach to RAS-targeted drug discovery 135, 136 . Two decades ago, several pharmaceutical companies successfully targeted FTase and developed orally available FTIs that were surprisingly well tolerated 137 . This effort was among the first successful applications of rational drug design. Unfortunately, FTIs lacked efficacy in clinical trials designed to treat tumours driven by mutant NRAS or KRAS, the two RAS isoforms that are associated with human cancer. The lack of efficacy proved to result from alternative prenylation, whereby NRAS and KRAS, which are normally not substrates for geranylgeranylation, could be modified by GGTase I in the presence of FTI 138 . This monumental failure has dampened enthusiasm in the biopharmaceutical industry for targeting the RAS trafficking pathway. Nevertheless, the approach retains its scientific logic and remains among the most viable. Indeed, both GGTase I inhibitors (GGTI) and ICMT inhibitors have shown promise in preclinical testing 139, 140 . Furthermore, as a protease, RCE1 is considered 'drugable' , and efforts at developing inhibitors against it have been reported 141 . Curiously, whereas genetic ablation of Icmt in mice has confirmed it to be a good target for anticancer drug discovery 142 , conditional knockout of Rce1 exacerbates KRAS4B-driven myeloproliferative disease 143 , suggesting that this enzyme may not be a good target for anticancer drug discovery. The biological basis for the differences between targeted disruption of ICMT and RCE1 in tumour models remains elusive and probably reflects the fact that RAS is but one of many substrates for these enzymes.
Conclusions
The GTP binding, GTP hydrolysis and switching functions of RAS require no PTMs, although some PTMs affect exchange rates. However, PTMs are required for the proper trafficking and localization of RAS within the cell, which, in turn, are essential for RAS function. CAAX modification by FTase, RCE1 and ICMT remodels the C terminus of the protein and creates a hydro phobic domain with affinity for membranes. Palmitoylation affinity traps NRAS and HRAS in Golgi membranes and initiates a cycle of traffic to and from the plasma membrane. Peptidyl-prolyl isomerization of HRAS at Pro179 by FKBP12 regulates depalmitoylation and thereby acts as a molecular timer for plasma membrane association. Diubiquitylation of NRAS and HRAS leads to their enrichment on endosomes. Phosphorylation of KRAS4B in its polybasic region engages a farnesyl-electrostatic switch that repositions the protein on endomembranes, a process that is associated with cell death when KRAS4B is activated. S-nitrosylation, ADP-ribosylation and glucosylation are modifications that do not affect the localization of RAS but do affect guanine nucleotide exchange rates. Thus, the location and function of RAS is determined by PTMs, making the enzymes that catalyse these modification s interesting targets for drug discovery.
Although much has been learned over the past two decades with regard to the PTM of RAS (FIG. 6) , many questions remain. Will recently developed GGTIs, alone or in common with FTIs, block RAS function without undue toxicity? What is the basis for the biological differences observed with ICMT versus RCE1 inhibition? Can substrates of these enzymes other than RAS explain the differences? Is there a RAS-specific cytosolic chaperone, and could farnesyl-peptide mimetics be developed to block its activity? Is there a specific PAT and thioesterase pair that palmitoylates and depalmitoylates RAS, and would these serve as good drug targets? Does inhibition of cis-trans prolyl isomerization by FK506 and rapamycin explain any of the activities of these widely used drugs? Further basic investigation into the network of PTMs that affect RAS trafficking and signalling will be required before these questions are answered.
